Pharma BD Deal Intelligence
Boehringer Ingelheim and Cue Biopharma entered a Collaboration and License Agreement to research, develop and commercialize differentiated B cell depletion molecules, including Cue's preclinical CUE-501 candidate for autoimmune disease. Cue receives $12 million upfront and is eligible for up to $345 million in research, development and commercial milestones plus royalties. Boehringer takes an exclusive, royalty-bearing, worldwide, sublicensable license and is responsible for all further research, development, manufacturing and commercialization. Collaborative research runs for a four-year research term, during which Cue is restricted from developing competing B cell depletion molecules.
← Browse all deals · How we score deals
More: 2025 deals · Boehringer Ingelheim International GmbH deals